

## North Yorkshire & York Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on the 3<sup>rd</sup> November 2021

### Classification of products:

- G** **Green drug** - Can be initiated and prescribed in all care settings **○**- Second line / alternative green drug
- ASR** **Amber Specialist Recommendation drug** - Can be recommended by a specialist for initiation in primary care
- ASI** **Amber Specialist Initiation drug** – Initiated by a specialist and transferred to primary care once the patient stabilised. In some cases there may be a further restriction for use outlined - these will be defined in each case.
- ASC** **Amber Shared Care drug** - These are specialist drugs which must be initiated by the specialist, but with the potential to transfer to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care
- R** **Red drug** - Drugs that should remain under the total responsibility of the specialist. Usually considered as “hospital only” drugs
- BLACK** **Not Approved** - Drugs that have been considered by the APC or other approved body and are not approved for prescribing within North Yorkshire & York.
- GREY** **Not Reviewed** - Drugs that haven't been reviewed by the APC yet. This usually means that no application has been received or that an application is in progress. These drugs are not normally considered appropriate for prescribing in North Yorkshire & York.



Product	Decision			Comments/notes
	Approved	Refused	Deferred	
<b>1) Requests deferred from previous meetings</b>				
Nil this month				
<b>2) New Requests</b>				
Upadacitinib for atopic dermatitis	✓ <b>R</b>			The clinicians feel there is an unmet need due to the poorer evidence base of baracitinib. Approved as 1st/2nd line option for atopic dermatitis on basis NICE TA delayed with no expected date of publication, and better efficacy data over the alternative which is baracitinib.
Tostran® 2% gel for Low libido in menopausal and women	✓ <b>G</b>			Topical testosterone approved for management of Low libido in menopausal and post-menopausal women. A supporting prescribing information sheet for GPs is in development.
<b>3) New formulations &amp; extensions to use</b>				
Nil this month				
<b>5) Products considered by NICE</b>				
TA732: Baloxavir marboxil for treating acute uncomplicated influenza (terminated appraisal)	✓ BLACK			The formulary will reflect the TAG – NHS England is the responsible commissioner.

## DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
<b>TA733: Inclisiran for treating primary hyper-cholesterolaemia or mixed dyslipidaemia</b>	✓ <b>G</b>			The formulary will reflect the TAG – CCGs are the responsible commissioner. Discussed and approved at Oct 2021 APC meeting
<b>TA734: Secukinumab for treating moderate to severe plaque psoriasis in children and young people</b>	✓ <b>R</b>			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>TA735: Tofacitinib for treating juvenile idiopathic arthritis</b>	✓ <b>R</b>			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>TA736: Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy</b>	✓ <b>R</b>			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>TA737: Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer</b>	✓ <b>R</b>			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>TA738: Berotralstat for preventing recurrent attacks of hereditary angioedema</b>	✓ <b>R</b>			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>6) Appeals against earlier decisions by the APC</b>				
None				
<b>7) Miscellaneous formulary decisions by the APC</b>				
Levomempromazine 6mg tablets	✓			Agreed to add a note to the formularies regarding the price of Levomepromazine tablets and that 6mg tablets should only be used in palliative care where quartering a 25mg tablet is unsuitable.

The following guidelines were presented to and approved at the November 2021 meeting of the APC:

- Nil this month.

DECISION SUMMARY

The following shared care guidelines were presented to and approved at the November 2021 meeting of the APC:

- Nil this month.

Other documents presented to and approved at the November 2021 meeting of the APC:

- Nil this month